Last reviewed · How we verify
Quadrivalent Inactivated Influenza High Dose — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Quadrivalent Inactivated Influenza High Dose (Quadrivalent Inactivated Influenza High Dose) — Sanofi Pasteur, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Quadrivalent Inactivated Influenza High Dose TARGET | Quadrivalent Inactivated Influenza High Dose | Sanofi Pasteur, a Sanofi Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Quadrivalent Inactivated Influenza High Dose CI watch — RSS
- Quadrivalent Inactivated Influenza High Dose CI watch — Atom
- Quadrivalent Inactivated Influenza High Dose CI watch — JSON
- Quadrivalent Inactivated Influenza High Dose alone — RSS
Cite this brief
Drug Landscape (2026). Quadrivalent Inactivated Influenza High Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/quadrivalent-inactivated-influenza-high-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab